Antibody-Drug Conjugates for Breast Cancer — Year in Review Series on Relevant New Datasets and Advances
Oncology Today with Dr Neil Love
00:00
TDXD vs TROP2 ADCs in Hormone Receptor–Positive Disease
Sara and Hope discuss Destiny Breast results, positioning TDXD for HER2-low and sequencing TROP2 ADCs later.
Play episode from 47:43
Transcript
